Overview

Long-Term Extension Study of Inhaled Nitric Oxide (iNO) for PAH

Status:
Active, not recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
An Open-Label Long-Term Safety Study of Inhaled Nitric Oxide (iNO) for Pulmonary Arterial Hypertension (PAH)
Phase:
Phase 3
Details
Lead Sponsor:
Bellerophon Pulse Technologies
Treatments:
Nitric Oxide